Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (11-20 of 234) with videos related to

Pageof 24
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 25, 2017
A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right DirectionJulio C Chavez, Frederick L Locke
Expert Opinion on Biological Therapy|April 30, 2017
Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapyFrederick L Locke, Marco L Davila
Nature Reviews. Clinical Oncology|February 10, 2025
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALLRawan G Faramand, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 13, 2012
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?Frederick L Locke, Gareth J Morgan
Best Practice & Research. Clinical Haematology|June 19, 2018
CAR T cell therapy for B-cell lymphomasJulio C Chavez, Frederick L Locke
Blood|September 21, 2023
CARs put age in the rearview mirrorCiara L Freeman, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
JACC. Cardiooncology|January 11, 2024
Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative TherapyBrandon Blue, Mohammed Alomar, Frederick L Locke
Future Oncology (London, England)|January 13, 2025
Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphomaFrederick L Locke, Jason R Westin, Christina To
The New England Journal of Medicine|September 21, 2023
Axicabtagene Ciloleucel in Large B-Cell Lymphoma. ReplyJason R Westin, Christina To, Frederick L Locke
Pageof 24

Showing results (11-20 of 234) with videos related to

Sort By:
Pageof 24
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 25, 2017
A Possible Cure for Refractory DLBCL: CARs Are Headed in the Right DirectionJulio C Chavez, Frederick L Locke
Expert Opinion on Biological Therapy|April 30, 2017
Regulatory challenges and considerations for the clinical application of CAR-T cell anti-cancer therapyFrederick L Locke, Marco L Davila
Nature Reviews. Clinical Oncology|February 10, 2025
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALLRawan G Faramand, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 13, 2012
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?Frederick L Locke, Gareth J Morgan
Best Practice & Research. Clinical Haematology|June 19, 2018
CAR T cell therapy for B-cell lymphomasJulio C Chavez, Frederick L Locke
Blood|September 21, 2023
CARs put age in the rearview mirrorCiara L Freeman, Frederick L Locke
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
JACC. Cardiooncology|January 11, 2024
Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative TherapyBrandon Blue, Mohammed Alomar, Frederick L Locke
Future Oncology (London, England)|January 13, 2025
Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphomaFrederick L Locke, Jason R Westin, Christina To
The New England Journal of Medicine|September 21, 2023
Axicabtagene Ciloleucel in Large B-Cell Lymphoma. ReplyJason R Westin, Christina To, Frederick L Locke
Pageof 24